Solving Customer Needs and Advancing Patient Safety through Novel Supercritical CO2 Solutions
NovaSterilis is global-serving sterilization process development company and equipment provider created to advance product safety and patient outcomes, with an emphasis on maintaining superior product functionality , through the development of a safer, gentler, and more effective terminal sterilization solution.
The NovaSterilis team is dedicated to advancing its vision and focusing on its mission for the benefit of all its stakeholders. We invite you, our customers and partners, to join us as we dedicate ourselves to improving the quality of people’s lives around the world through a commitment to daily excellence.
NovaSterilis History
Advancing patient healing and outcomes through novel supercritical CO2 solutions
- NovaSterilis was launched in 2001 to commercialize a broad range of emerging combination (i.e. biologic/polymeric) products that were being introduced to the medical device market. These new products required gentle, low temperature, non-reactive sterilants with the ability to penetrate through packaging and product. Supercritical CO2,with its unique physical and chemical properties, proved to be an ideal target platform.
- By 2006, NovaSterilis had developed an effective, safe and commercially viable terminal sterilization process using scCO2. The Company patented its novel sterilization process (the Nova Process™) and began commercial operations in 2007 selling the Nova2200™ equipment and a sterilization additive, NovaKill™.
- NovaSterilis’ initial market focus was the human tissue banking industry. By 2015 regulatory agencies in the U.S.A. and Australia had approved products that utilized the Nova Process™ as the terminal sterilization modality. Over that time, allograft tissue sterilized with the Nova Process has been delivered and used worldwide in more than 500,000 surgeries.
- In Q4 2017, the Company completed a renovation of its facilities and expanded its team in order to continue to meet the evolving needs of its customers.
NovaSterilis continues to serve several industries including tissue banking, regenerative medicine, and medical device markets with its equipment, additives, and processes. Over the years NovaSterilis has also worked with numerous customers around the globe performing contract research on applications of scCO2 across a broad range of materials including biologic, polymeric, small molecule, large molecule, food, and agricultural materials.